Atrial Fibrillation Trial, Recruiting NCT06363604 Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06363604
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 85 years old
  • You have persistent atrial fibrillation (an irregular heartbeat lasting at least 1 week) that is causing symptoms, is not caused by a heart valve problem, and has not been controlled by at least one heart rhythm medication
  • You are planning to have a catheter ablation procedure to treat your atrial fibrillation
  • You are willing to give your consent to participate and are able to attend follow-up appointments and assessments

Who may not be able to join:

  • You have had a heart attack in the last 3 months, are currently experiencing acute heart failure, or have had a stroke within the last 3 months
  • You are currently on a waiting list for a heart transplant
  • Your doctors expect you to live less than 1 year
  • You have a bleeding disorder that means you cannot safely take blood-thinning medication
  • You have a blood clot in the upper left chamber of your heart
  • You have severe heart failure (confirm with trial site) or your heart's pumping strength is significantly reduced (below 40%)
  • You have a cancer that is not under control
  • You have significant liver or kidney problems, based on specific blood and kidney function test results (confirm with trial site)
  • You have previously had a catheter ablation procedure for atrial fibrillation, or have had heart surgery in the past
  • You are pregnant, breastfeeding, planning to become pregnant, or are of childbearing age and not using reliable contraception

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yigang LI, Dr., Xinhua Hospital, Shanghai Jiaotong University School of Medicine

Phone: +8613585563975

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 December 2023
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Recurrence of atrial arrhythmias

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov